Belite Bio Inc is a San Diego based clinical stage biopharmaceutical drug development company targeting untreatable age-related metabolic diseases, including macular degeneration, liver disease and diabetes.
Developed from our anti-RBP4 technology platform, our lead candidate, LBS-008, is currently in a Phase I clinical trial for dry age-related macular degeneration and its juvenile form, Stargardt disease. LBS-008 has received Orphan Drug Status in the US and Europe, as well as Rare Pediatric Disease Status in the US.